{"organizations": [], "uuid": "7424f1504f2e92bb7b3bbc5f215f024191e1634d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-evotec-apeiron-biologics-receive-m/brief-evotec-apeiron-biologics-receive-milestone-payment-from-sanofi-idUSFWN1P201G", "country": "US", "domain_rank": 408, "title": "BRIEF-Evotec, Apeiron Biologics receive milestone payment from Sanofi", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-01-08T14:45:00.000+02:00", "replies_count": 0, "uuid": "7424f1504f2e92bb7b3bbc5f215f024191e1634d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-evotec-apeiron-biologics-receive-m/brief-evotec-apeiron-biologics-receive-milestone-payment-from-sanofi-idUSFWN1P201G", "ord_in_thread": 0, "title": "BRIEF-Evotec, Apeiron Biologics receive milestone payment from Sanofi", "locations": [], "entities": {"persons": [], "locations": [{"name": "frankfurt", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "apeiron biologics", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Evotec Ag:\n* SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​\n* SAYS ‍MILESTONE PAYMENT OF EUR 3 M WILL BE SPLIT EQUALLY BETWEEN TWO BIOTECH COMPANIES​\n* SAYS ‍SUCCESS PAYMENT WAS TRIGGERED WHEN PARTNERS SUCCESSFULLY ADVANCED AN UNDISCLOSED, NOVEL IMMUNO-ONCOLOGY SMALL MOLECULE INTO LATE-STAGE PRE-CLINICAL DEVELOPMENT​\n* SAYS ‍UNDER ALLIANCE, THREE COMPANIES WORK TOGETHER TO IDENTIFY SMALL MOLECULE LEADS AND TARGETS FOR NEXT-GENERATION THERAPIES IN IMMUNO-ONCOLOGY​ Source text for Eikon: Further company coverage: (Frankfurt newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T14:45:00.000+02:00", "crawled": "2018-01-09T17:12:23.015+02:00", "highlightTitle": ""}